TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis

被引：0
|
作者：
M. Cole
C. Yap
C. Buckley
W. F. Ng
I. McInnes
A. Filer
S. Siebert
A. Pratt
J. D. Isaacs
D. D. Stocken
机构：
[1] Newcastle University,Population Health Sciences Institute
[2] The Institute of Cancer Research,Clinical Trials and Statistics Unit
[3] London,School of Immunity and Infection
[4] University of Birmingham,Translational and Clinical Research Institute
[5] Newcastle University,College of Medical, Veterinary and Life Sciences
[6] University of Glasgow,Leeds Institute of Clinical Trials Research
[7] University of Leeds,undefined
来源：
Trials | / 22卷
关键词：
CRM; Dose-finding; Adaptive; Early-phase; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease
    Joshua J. Solomon
    Sonye K. Danoff
    Hilary J. Goldberg
    Felix Woodhead
    Martin Kolb
    Daniel C. Chambers
    Donna DiFranco
    Cathy Spino
    Shana Haynes-Harp
    Shelley Hurwitz
    Elizabeth B. Peters
    Paul F. Dellaripa
    Ivan O. Rosas
    Advances in Therapy, 2019, 36 : 3279 - 3287
  • [42] The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease
    Solomon, Joshua J.
    Danoff, Sonye K.
    Goldberg, Hilary J.
    Woodhead, Felix
    Kolb, Martin
    Chambers, Daniel C.
    DiFranco, Donna
    Spino, Cathy
    Haynes-Harp, Shana
    Hurwitz, Shelley
    Peters, Elizabeth B.
    Dellaripa, Paul F.
    Rosas, Ivan O.
    ADVANCES IN THERAPY, 2019, 36 (11) : 3279 - 3287
  • [43] Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination
    Blair, Gordon W.
    Appleton, Jason P.
    Law, Zhe Kang
    Doubal, Fergus
    Flaherty, Katie
    Dooley, Richard
    Shuler, Kirsten
    Richardson, Carla
    Hamilton, Iona
    Shi, Yulu
    Stringer, Michael
    Boyd, Julia
    Thrippleton, Michael J.
    Sprigg, Nikola
    Bath, Philip M.
    Wardlaw, Joanna M.
    INTERNATIONAL JOURNAL OF STROKE, 2018, 13 (05) : 530 - 538
  • [44] SURPASS trial design: A phase 1 dose escalation trial to assess safety and efficacy of ADP-A2M4CD8 in HLA-A2+patients with MAGE-A4+tumors
    Hong, David
    Butler, Marcus
    Johnson, Melissa
    Johanns, Tanner
    Brophy, Francine
    Dryer-Minnerly, Rebecca
    Trivedi, Trupti
    Amado, Rafael
    Fracasso, Paula
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [45] A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy
    Zhang, Wenhui
    Kernstock, Robert M.
    Karrer, Erik E.
    Cohen, Stanley B.
    Chindalore, Vishala L.
    Kivitz, Alan J.
    Blahunka, Paul C.
    Delgado-Herrera, Leticia
    Zeiher, Bernhardt G.
    Samberg, Nancy L.
    Garg, Jay P.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (04): : 259 - 268
  • [46] Safety Analysis of a New Generation Freeze-Dried Plasma Product: Report of a Dose-Escalation, Phase 1 Clinical Trial
    Cancelas, Jose
    Rugg, Neeta
    Nestheide, Shawnagay
    King, Melissa
    Snyder, Michele
    Pehta, Joan C.
    Macdonald, Victor
    Valiyaveettil, Manoj
    Atkinson, Andrew
    TRANSFUSION, 2018, 58 : 10A - 10A
  • [47] FIRST HUMAN DOSE OF THE ANTI-C5A RECEPTOR-TARGETING, HUMAN MONOCLONAL ANTIBODY NNC0215-0384 IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PHASE 1, RANDOMISED, DOUBLE-BLIND, SINGLE-DOSE, DOSE-ESCALATION TRIAL
    Wagner, F.
    Lange, C. F.
    Nowak, M.
    Ignatenko, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 499 - 499
  • [48] Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial
    McGree, J. M.
    Hockham, C.
    Kotwal, S.
    Wilcox, A.
    Bassi, A.
    Pollock, C.
    Burrell, L. M.
    Snelling, T.
    Jha, V.
    Jardine, M.
    Jones, M.
    TRIALS, 2022, 23 (01)
  • [49] Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial
    J. M. McGree
    C. Hockham
    S. Kotwal
    A. Wilcox
    A. Bassi
    C. Pollock
    L. M. Burrell
    T. Snelling
    V. Jha
    M. Jardine
    M. Jones
    Trials, 23
  • [50] A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population
    Quintana, Melanie
    Li, Daniel H.
    Albertson, Tina M.
    Connor, Jason T.
    CONTEMPORARY CLINICAL TRIALS, 2016, 48 : 153 - 165
12345